- Home
- YQ vs LPCN Comparison
YQ vs LPCN Comparison
Compare YQ & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YQ
- LPCN
- Stock Information
- Founded
- YQ 2012
- LPCN 1997
- Country
- YQ China
- LPCN United States
- Employees
- YQ N/A
- LPCN N/A
- Industry
- YQ Other Consumer Services
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- YQ Real Estate
- LPCN Health Care
- Exchange
- YQ Nasdaq
- LPCN Nasdaq
- Market Cap
- YQ 15.2M
- LPCN 16.1M
- IPO Year
- YQ 2020
- LPCN N/A
- Fundamental
- Price
- YQ $1.89
- LPCN $3.16
- Analyst Decision
- YQ
- LPCN Strong Buy
- Analyst Count
- YQ 0
- LPCN 1
- Target Price
- YQ N/A
- LPCN $10.00
- AVG Volume (30 Days)
- YQ 33.0K
- LPCN 22.1K
- Earning Date
- YQ 06-04-2025
- LPCN 05-08-2025
- Dividend Yield
- YQ N/A
- LPCN N/A
- EPS Growth
- YQ N/A
- LPCN N/A
- EPS
- YQ N/A
- LPCN N/A
- Revenue
- YQ $25,922,648.00
- LPCN $3,674,834.00
- Revenue This Year
- YQ N/A
- LPCN N/A
- Revenue Next Year
- YQ N/A
- LPCN N/A
- P/E Ratio
- YQ N/A
- LPCN N/A
- Revenue Growth
- YQ 10.68
- LPCN N/A
- 52 Week Low
- YQ $1.26
- LPCN $2.75
- 52 Week High
- YQ $3.19
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- YQ 49.62
- LPCN 48.60
- Support Level
- YQ $1.99
- LPCN $2.68
- Resistance Level
- YQ $2.50
- LPCN $3.46
- Average True Range (ATR)
- YQ 0.33
- LPCN 0.33
- MACD
- YQ -0.00
- LPCN -0.02
- Stochastic Oscillator
- YQ 25.23
- LPCN 51.97
About YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.